With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...

WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central review–assessed PFS as the primary end point. Sunvozertinib improved PFS ...

Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...

A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David ...

Paul G. Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment. Paul G. Richardson, MD, director of Clinical Research ...

Determining the optimal second-line approach in patients with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed either on 1 or 2 lines of therapy and who had ...

Explore why community and academic oncologists collaborate, share expertise, and deliver faster, more nuanced care for complex patients. The era of the "academic master" is over. Modern oncology ...

In the United States, the vast majority of oncology care is delivered within community-based centers, yet the most ...

The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient advocates to discuss the latest breakthroughs and challenges in lung cancer care.

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse strategies like BCMA CAR-T and genomic profiling. Dr. Nooka traces the 15-year ...

Dr. Ajay Nooka, director of the Myeloma program at Winship Cancer Institute of Emory University, simplifies the International Myeloma Working Group criteria for disease progressio ...